Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

3/28/2024 Pharmaceutical Drug Production in Russia (February 2024)

In January–February 2024, Russian manufacturers produced 124.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 22.8% from the same period in 2023. In physical terms, it was 649 million packages, up 6.4% from January–February 2023. If calculated in minimum dosage units (MDU), the manufacture was 13.2 billion, up 10.8% from the same periods in 2023.

3/27/2024 Inflation Rates in the Russian Pharmaceutical Retail Market (January 2024)

In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The highest price growth rates were seen in early 2023; as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023. By the end of the year, the prices had stabilized, dropping to a year-low. January 2024, however, saw a slight upward trend; the price index was 26.4% from January 2023.

3/18/2024 Study RNC Pharma and Medvestnik: 63% of Russian Doctors Back Initiative to Allow Early Retirement in Private Hospitals, 35% Against

49.2% of Russian physicians fully support the initiative to allow doctors working in private medical institutions early retirement, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.

3/13/2024 Study by RNC Pharma and Medvestnik: 37% of Russian Doctors Do Not Believe in Quick Launch of New System of Remuneration, 46% Say New System Will Lead to Lower Salaries

Most Russian physicians remain pessimistic regarding the new system of remuneration. Only 9.6% of the doctors expect higher salaries soon, saying that the chances of implementing the project are high, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. Another 15.7% of the respondents believe that the system will be launched only if the economic situation improves. Finally, 21.6% do not expect any rapid changes, saying that even if it is launched as quickly as possible, it will take several years before the system launches nationwide.

3/11/2024 Study by RNC Pharma and Medvestnik: 53% of Russian Doctors Against ICD-11 Implementation

Most Russian physicians (52.8%) support the suspension of ICD-11 implementation in the country, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. In particular, 34.4% fully support the suspension, believing that a number of ICD-11 sections promote the LGBT agenda and contradict medical science. Another 18.4%, while saying that the suspension of ICD-11 in its current form may be appropriate, believe that the implementation can be resumed provided that the controversial sections are excluded.

All news [406]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.